<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439164</url>
  </required_header>
  <id_info>
    <org_study_id>2014MP06</org_study_id>
    <nct_id>NCT02439164</nct_id>
  </id_info>
  <brief_title>Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma</brief_title>
  <official_title>Cohort Study of Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma: Comparison With a Control Group Without Intracranial Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <brief_summary>
    <textblock>
      Sedation in the operating room, the Post Anesthesia Care Unit and the Intensive Care Unit is
      common and often necessary for patients with intracranial brain tumor. Repeated neurological
      function assessments is needed in those locations, especially in patients with tumors in or
      near eloquent regions, this is to monitor their neurologic performance to determine if there
      are alterations that require treatment. Some slowly infiltrative low-grade gliomas near
      eloquent regions do not show any detectable neurologic deficits, perhaps from reorganization,
      but with sedation by some sedatives such as benzodiazepine midazolam and anesthetic hypnotic
      propofol, the disease may seem much worse resulting in inappropriately aggressive treatment.
      This may be especially problematic in patients undergoing awake craniotomy for tumors in
      eloquent regions.

      This is a single-center perspective study. Patients will be mildly sedated to keep them
      responsive and cooperative. Motor and sensory function will be evaluated before and after
      mild sedation. Specific benzodiazepine antagonist will be used if sedated by midazolam.

      The purpose of this study is to observe if commonly used benzodiazepine midazolam exacerbates
      or unmasks motor and sensory function in patients with intracranial eloquent area gliomas.

      Hypothesis:

      mild sedation can unmasks or exacerbate motor and sensory deficits in patients with eloquent
      area glioma but not in non-neurosurgical patients/healthy volunteers. If the neurologic
      deficits induced by benzodiazepine agonist, then can be reversed by flumazenil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2015</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test</measure>
    <time_frame>after sedation</time_frame>
    <description>this is a focal neurologic deficits induced by sedatives, the outcome is the performing time changes after sedation as : sedation-baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With OAA/S=4 After Sedation</measure>
    <time_frame>withing 1 hour</time_frame>
    <description>OAA/S is Observer Assessment of Sedation with 5 levels (5 = alert, 4 = lethargic, 3 = aroused by voice, 2 = aroused by shaking, 1 = deep sleep), all participants have to achieve OAA/S=4 after sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Blood Pressure (MAP) as a Measure of Physiological Change</measure>
    <time_frame>1 hour</time_frame>
    <description>The MAP was measured at three time points: baseline, sedation and sedation reversal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate as a Measure of Physiological Change</measure>
    <time_frame>1 hour</time_frame>
    <description>The HR was measured at three time points: baseline, sedation and sedation reversal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Glioma Pathological Diagnose as a Measure of Tumor Type</measure>
    <time_frame>2 weeks</time_frame>
    <description>the WHO grade and the type of glioma (WHO glioma grade I~II is regarded as low grade glioma, WHO glioma grade III~IV is regarded as high grade glioma)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Glioma group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-neurosurgical group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used</description>
    <arm_group_label>Glioma group</arm_group_label>
    <arm_group_label>non-neurosurgical group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-60 year-old

          -  American Society of Anesthesiology(ASA) status I~II

          -  Elective craniotomy patients with supratentorial eloquent glioma diagnosed by MRI (In
             control group: volunteers without neuro-diseases)

        Exclusion Criteria:

          -  Unable to comprehend and cooperate with the neurologic examination

          -  Impaired mental status

          -  Taking sedative drugs in the past 24 hours

          -  Taking pain reliever in the past 24 hours

          -  Drug and/or alcohol abuse

          -  Pregnant and/o lactating women

          -  Recurrent brain tumors

          -  Multiple brain tumors

          -  Accepting radiotherapy or chemotherapy

          -  Complicated with intracranial trauma and vascular diseases

          -  Complicated with grand mal epilepsy ( in midazolam group)

          -  Complicated with neuromuscular diseases

          -  Complicated with cutaneous paresthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>July 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2017</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Nan Lin</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>sedation</keyword>
  <keyword>eloquent area glioma</keyword>
  <keyword>neurologic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glioma Group</title>
          <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
        <group group_id="P2">
          <title>Non-neurosurgical Group</title>
          <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient in non-neurosurgical group was dropped out because he reported his carotid disease history after the task testing. In glioma group, pathological diagnosis displayed two with metastasis and one with meningioma, which were excluded during follow-up. There are 15 in the glioma group and 17 in the control group for the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Glioma Group</title>
          <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
        <group group_id="B2">
          <title>Non-neurosurgical Group</title>
          <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years old</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="9"/>
                    <measurement group_id="B2" value="35" spread="7"/>
                    <measurement group_id="B3" value="40" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="14.0"/>
                    <measurement group_id="B2" value="75.8" spread="5.1"/>
                    <measurement group_id="B3" value="70.7" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>primary school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>middle school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test</title>
        <description>this is a focal neurologic deficits induced by sedatives, the outcome is the performing time changes after sedation as : sedation-baseline.</description>
        <time_frame>after sedation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glioma Group</title>
            <description>Patients in this group will be administered sedative midazolam titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
          <group group_id="O2">
            <title>Non-neurosurgical Group</title>
            <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
        </group_list>
        <measure>
          <title>Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test</title>
          <description>this is a focal neurologic deficits induced by sedatives, the outcome is the performing time changes after sedation as : sedation-baseline.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline for contralesional hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="15.9"/>
                    <measurement group_id="O2" value="19.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after sedation for contralesional hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="32.4"/>
                    <measurement group_id="O2" value="21.4" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline for ipsilesional hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="7.1"/>
                    <measurement group_id="O2" value="19.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after sedation for ipsilesional hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="16.6"/>
                    <measurement group_id="O2" value="21.4" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>bonferroni correction was used for post hoc analysis, P value less than 0.05 indicated statistical significance.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>23.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.16</ci_lower_limit>
            <ci_upper_limit>32.87</ci_upper_limit>
            <estimate_desc>this described the difference during midazolam sedation between the glioma and control group without dividing into subgroups.</estimate_desc>
            <other_analysis_desc>Oneway Analysis of Variance (ANOVA) was used to test the difference among hands in a certain time point. General linear model for repeated measures ANOVA was used to analyze the time difference of test before and after drug administration,</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With OAA/S=4 After Sedation</title>
        <description>OAA/S is Observer Assessment of Sedation with 5 levels (5 = alert, 4 = lethargic, 3 = aroused by voice, 2 = aroused by shaking, 1 = deep sleep), all participants have to achieve OAA/S=4 after sedation.</description>
        <time_frame>withing 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glioma Group</title>
            <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
          <group group_id="O2">
            <title>Non-neurosurgical Group</title>
            <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With OAA/S=4 After Sedation</title>
          <description>OAA/S is Observer Assessment of Sedation with 5 levels (5 = alert, 4 = lethargic, 3 = aroused by voice, 2 = aroused by shaking, 1 = deep sleep), all participants have to achieve OAA/S=4 after sedation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Blood Pressure (MAP) as a Measure of Physiological Change</title>
        <description>The MAP was measured at three time points: baseline, sedation and sedation reversal.</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glioma Group</title>
            <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
          <group group_id="O2">
            <title>Non-neurosurgical Group</title>
            <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Blood Pressure (MAP) as a Measure of Physiological Change</title>
          <description>The MAP was measured at three time points: baseline, sedation and sedation reversal.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="13.5"/>
                    <measurement group_id="O2" value="95.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" spread="9.5"/>
                    <measurement group_id="O2" value="91.2" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation reversal MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="13.6"/>
                    <measurement group_id="O2" value="88.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate as a Measure of Physiological Change</title>
        <description>The HR was measured at three time points: baseline, sedation and sedation reversal.</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glioma Group</title>
            <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
          <group group_id="O2">
            <title>Non-neurosurgical Group</title>
            <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate as a Measure of Physiological Change</title>
          <description>The HR was measured at three time points: baseline, sedation and sedation reversal.</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" spread="15.6"/>
                    <measurement group_id="O2" value="79.0" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" spread="14.3"/>
                    <measurement group_id="O2" value="79.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation reversal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" spread="17.7"/>
                    <measurement group_id="O2" value="71.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Glioma Pathological Diagnose as a Measure of Tumor Type</title>
        <description>the WHO grade and the type of glioma (WHO glioma grade I~II is regarded as low grade glioma, WHO glioma grade III~IV is regarded as high grade glioma)</description>
        <time_frame>2 weeks</time_frame>
        <population>In non-neurosurgical group, patients were not diagnosed as glioma, so the belowed &quot;outcome measure data table&quot; could not indicate the number of glioma grade.</population>
        <group_list>
          <group group_id="O1">
            <title>Glioma Group</title>
            <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Glioma Pathological Diagnose as a Measure of Tumor Type</title>
          <description>the WHO grade and the type of glioma (WHO glioma grade I~II is regarded as low grade glioma, WHO glioma grade III~IV is regarded as high grade glioma)</description>
          <population>In non-neurosurgical group, patients were not diagnosed as glioma, so the belowed &quot;outcome measure data table&quot; could not indicate the number of glioma grade.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>low grade glioma</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>high grade glioma</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 hour</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glioma Group</title>
          <description>Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
        <group group_id="E2">
          <title>Non-neurosurgical Group</title>
          <description>patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
Midazolam: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used as a reversal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nan Lin</name_or_title>
      <organization>Beijing Tiantan Hospital</organization>
      <phone>861067096658</phone>
      <email>linnan127@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

